APA (7th ed.) Citation

Neelima Denduluri, Janet L. Espirito, Michelle D. Hackshaw, Chuck Wentworth, Tamy Recchia, & Winghan J. Kwong. (2022). Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States. Adis, Springer Healthcare.

Chicago Style (17th ed.) Citation

Neelima Denduluri, Janet L. Espirito, Michelle D. Hackshaw, Chuck Wentworth, Tamy Recchia, and Winghan J. Kwong. Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States. Adis, Springer Healthcare, 2022.

MLA (9th ed.) Citation

Neelima Denduluri, et al. Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States. Adis, Springer Healthcare, 2022.